I-Mab

168 articles about I-Mab

• I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million

  7/29/2021

  I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that its Board of Directors has authorized a new stock repurchase program.

• I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China

  7/28/2021

  I-Mab announced that an IND application for the initiation of a phase 2 clinical trial of efineptakin alfa in combination with anti-PD-1 antibody in patients with advanced solid tumors, including triple-negative breast cancer and head and neck cancers, has been accepted by the Center for Drug Evaluation of the China National Medical Products Administration.

• I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms

  7/9/2021

  I-Mab today announced the signing of two new collaborations with emerging biotech companies in China to strengthen its next-generation innovation pipeline.

• I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio

  7/1/2021

  I-Mab today announced multiple advancements in its 4-1BB bispecific antibody portfolio.

• I-Mab Honored with Top Rankings by Institutional Investor

  6/30/2021

  I-Mab today announced that it was ranked among the top companies by leading global financial publication Institutional Investor in both the "Honored Companies" and "Best CFO" categories, according to its 2021 All-Asia Executive Team survey.

• I-Mab Announces Upcoming Participation at July Conference

  6/29/2021

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conference in July.

• I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus

  6/25/2021

  I-Mab today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to initiate a phase 1b trial of felzartamab, a CD38 antibody, in patients with systemic lupus erythematosus (SLE).

• I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board

  6/21/2021

  I-Mab today announced the appointment of Andrew Zhu , MD, PhD, to the Company's Scientific Advisory Board.

• I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab

  6/2/2021

  I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that it will hold a call with investors on Monday, June 7 at 8:00 a.m. ET to provide an in-depth clinical data analysis of its U.S. phase 1 study of uliledlimab in combination with atezolizumab in patients with advanced cancers.

• I-Mab Appoints Ruyi He and Rong Shao to Board of Directors

  6/1/2021

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that Dr. Ruyi He and Professor Rong Shao have been elected as members of the Company's board of directors.

• I-Mab Announces Upcoming Participation at June 2021 Conferences

  5/27/2021

  I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced its participation in the following conferences in June.

• I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021

  5/19/2021

  Uliledlimab is a highly differentiated CD73 antibody with a unique epitope that confers pharmacological advantages Data from U.S. phase 1 dose escalation trial demonstrates favorable safety and tolerability with no dose-limiting toxicities; preliminary clinical activity of uliledlimab has been observed in patients with advanced cancers

• I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

  5/18/2021

  I-Mab today announced that the first patient has been dosed in an abbreviated combination clinical study (NCT04202003) of lemzoparlimab (also known as TJC4) with azacitidine (AZA) in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in China.

• I-Mab Added to MSCI China Index

  5/13/2021

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab has been selected for inclusion in the MSCI China All Shares Index, following MSCI's most recent semi-annual review.

• I-Mab Announces Upcoming Participation at May 2021 Conferences

  4/29/2021

  I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced its participation in the following conferences in May.

• I-Mab Filed 2020 Annual Report on Form 20-F

  4/28/2021

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company has filed its annual report on Form 20-F for the full year ended December 31, 2020 with the U.S. Securities and Exchange Commission

• I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis

  4/26/2021

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced positive topline results from its regional multi-center, randomized, double-blind and placebo-controlled phase 2 study

• I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

  4/14/2021

  I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its abstract on proprietary and highly differentiated CD73 antibody uliledlimab (also known as TJD5, or TJ004309) has been selected for detailed poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually June 4-8, 2021.

• I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors

  4/6/2021

  I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter “ABL”), a South Korean biotech specializing in bispecific antibody technology, jointly announced that the first patient has been dosed in a phase 1 trial for bispecific antibody TJ-L14B/ABL50

• I-Mab Announces Upcoming Participation at April 2021 Conferences

  3/31/2021

  I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologic, announced its participation in the following conferences in April.